J.P. Morgan increases stake in Kuros Biosciences

J.P. Morgan has increased its stake in Kuros Biosciences, a Swiss company specializing in bone regeneration products. According to recent disclosures, the Wall Street bank now holds more than five percent of the voting rights, with over half of that position held directly in shares.

This move comes despite a significant decline in Kuros Biosciences' stock price. After seeing its value increase nearly sixfold in 2024, the stock has dropped approximately 34 percent since the beginning of the current year, trading below 19 Swiss francs. This decline follows a ‘Buy’ recommendation from UBS, which had set a twelve-month price target of 33 francs.